Compare Stocks: NTRB, NERV, IMUX, and DERM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.53 -0.3%	$6.79	$4.31 ▼ $9.56	$212.53M	1.08	224,104 shs	74,230 shs
IMUX Immunic	$16.30 -1.2%	$14.98	$5.06 ▼ $17.43	$222.40M	1.41	275,354 shs	162,879 shs
NERV Minerva Neurosciences	$5.13 -5.5%	$4.51	$1.93 ▼ $12.46	$244.96M	-0.1	219,297 shs	89,895 shs
NTRB Nutriband	$4.62 +2.7%	$3.21	$2.80 ▼ $8.63	$56.16M	1.98	14,100 shs	12,956 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	+0.27%	+10.87%	+18.52%	+21.77%	+1.75%
IMUX Immunic	+0.43%	+0.24%	+19.41%	+10.15%	+87.39%
NERV Minerva Neurosciences	+8.60%	+13.36%	+29.29%	+8.60%	+131.06%
NTRB Nutriband	-6.83%	+26.76%	+50.25%	+23.63%	-30.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.53 -0.3%	$6.79	$4.31 ▼ $9.56	$212.53M	1.08	224,104 shs	74,230 shs
IMUX Immunic	$16.30 -1.2%	$14.98	$5.06 ▼ $17.43	$222.40M	1.41	275,354 shs	162,879 shs
NERV Minerva Neurosciences	$5.13 -5.5%	$4.51	$1.93 ▼ $12.46	$244.96M	-0.1	219,297 shs	89,895 shs
NTRB Nutriband	$4.62 +2.7%	$3.21	$2.80 ▼ $8.63	$56.16M	1.98	14,100 shs	12,956 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	+0.27%	+10.87%	+18.52%	+21.77%	+1.75%
IMUX Immunic	+0.43%	+0.24%	+19.41%	+10.15%	+87.39%
NERV Minerva Neurosciences	+8.60%	+13.36%	+29.29%	+8.60%	+131.06%
NTRB Nutriband	-6.83%	+26.76%	+50.25%	+23.63%	-30.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	2.25	Hold	$14.00	85.92% Upside
IMUX Immunic	3.00	Buy	$47.25	189.88% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	101.43% Upside
NTRB Nutriband	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest NTRB, NERV, IMUX, and DERM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/13/2026	DERM Journey Medical	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00 ➝ $15.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/29/2026	IMUX Immunic	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	DERM Journey Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/17/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/3/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/29/2026	IMUX Immunic	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$68.18M	3.12	N/A	N/A	$1.14 per share	6.61
IMUX Immunic	N/A	N/A	N/A	N/A	$9.35 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.47) per share	N/A
NTRB Nutriband	$1.80M	31.16	N/A	N/A	$0.55 per share	8.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$11.43M	-$0.22	N/A	8.37	N/A	-8.95%	-20.23%	-6.60%	11/11/2026 (Estimated)
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	11/12/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
NTRB Nutriband	-$8.23M	-$2.58	N/A	N/A	N/A	-448.25%	-112.64%	-97.86%	9/30/2026 (Estimated)

Latest NTRB, NERV, IMUX, and DERM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	DERM Journey Medical	-$0.0225	-$0.01	+$0.0125	-$0.01	$18.36 million	$18.51 million
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A
6/11/2026	Q1 2027	NTRB Nutriband	N/A	-$0.10	N/A	-$0.10	N/A	$0.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	0.64	1.59	1.41
IMUX Immunic	N/A	5.05	5.05
NERV Minerva Neurosciences	N/A	20.15	20.14
NTRB Nutriband	N/A	5.26	5.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
IMUX Immunic	51.82%
NERV Minerva Neurosciences	34.56%
NTRB Nutriband	19.70%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	14.53%
IMUX Immunic	5.49%
NERV Minerva Neurosciences	1.70%
NTRB Nutriband	52.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	28.22 million	24.12 million	N/A
IMUX Immunic	70	13.64 million	12.90 million	Optionable
NERV Minerva Neurosciences	9	47.75 million	46.94 million	Not Optionable
NTRB Nutriband	10	12.16 million	5.81 million	Not Optionable

NTRB, NERV, IMUX, and DERM Headlines

Recent News About These Companies

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

August 13, 2026 | globenewswire.com

Nutriband shareholders approve proposals and expand board leadership

June 23, 2026 | theglobeandmail.com

Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference

May 15, 2026 | globenewswire.com

Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

April 22, 2026 | globenewswire.com

Nutriband Advances Lead Abuse-Deterrent Fentanyl Patch Branding

April 7, 2026 | tipranks.com

Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

March 30, 2026 | globenewswire.com

Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica

March 18, 2026 | finance.yahoo.com

Nutriband Wins Costa Rica OK for Product

March 18, 2026 | baystreet.ca

Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

February 17, 2026 | globenewswire.com

Nutriband Cancels Planned Sale of Pocono Pharmaceuticals

February 14, 2026 | theglobeandmail.com

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

January 30, 2026 | globenewswire.com

The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable

January 29, 2026 | finance.yahoo.com

Nutriband says ‘committed’ to shareholder value as ‘number one focus’

January 1, 2026 | finance.yahoo.com

Nutriband Inc. CEO Shares 2025 Achievements and 2026 Outlook in Letter to Shareholders

December 31, 2025 | quiverquant.comQ

Nutriband CEO Publishes Letter to Shareholders

December 31, 2025 | globenewswire.com

Nutriband Divests Pocono Stake to Fund AVERSA Fentanyl

December 30, 2025 | tipranks.com

What’s driving Nutriband shares higher today?

December 29, 2025 | msn.com

Nutriband stock soars on sale of Pocono Pharmaceutical stake

December 29, 2025 | za.investing.com

Nutriband Inc. Sells 90% Stake in Pocono Pharmaceutical to Earthvision Bio for $5 Million

December 29, 2025 | quiverquant.comQ

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

December 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB, NERV, IMUX, and DERM Company Descriptions

Journey Medical NASDAQ:DERM

$7.53 -0.02 (-0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$7.54 +0.01 (+0.20%)

As of 04:10 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Immunic NASDAQ:IMUX

$16.30 -0.19 (-1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$16.05 -0.25 (-1.53%)

As of 05:31 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Minerva Neurosciences NASDAQ:NERV

$5.13 -0.30 (-5.52%)

Closing price 04:00 PM Eastern

Extended Trading

$5.12 0.00 (-0.10%)

As of 06:19 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Nutriband NASDAQ:NTRB

$4.62 +0.12 (+2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$4.61 -0.01 (-0.32%)

As of 04:10 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTRB, NERV, IMUX, and DERM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTRB, NERV, IMUX, and DERM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTRB, NERV, IMUX, and DERM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB, NERV, IMUX, and DERM Company Descriptions

Journey Medical NASDAQ:DERM

Immunic NASDAQ:IMUX

Minerva Neurosciences NASDAQ:NERV

Nutriband NASDAQ:NTRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTRB, NERV, IMUX, and DERM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTRB, NERV, IMUX, and DERM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTRB, NERV, IMUX, and DERM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB, NERV, IMUX, and DERM Company Descriptions

Journey Medical NASDAQ:DERM

Immunic NASDAQ:IMUX

Minerva Neurosciences NASDAQ:NERV

Nutriband NASDAQ:NTRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools